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Autoimmune polyendocrine 
syndrome type 1: case report 
and review of literature
Síndrome poliglandular autoimune tipo 1: 
descrição de caso e revisão da literatura
Fernanda Guimarães Weiler1, Magnus R. Dias-da-Silva2, Marise Lazaretti-Castro1
SUMMARY
Autoimmune polyendocrine syndrome type 1 (APECED) is a rare autosomal recessive disorder 
characterized by autoimmune multiorgan attack. The disease is caused by mutations in the au-
toimmune regulator gene (AIRE), resulting in defective AIRE protein, which is essential for self-
tolerance. Clinical manifestations are widely variable. Although the classic triad is composed by 
mucocutaneous candidiasis, hypoparathyroidism and adrenal failure, many other components 
may develop. Treatment is based on supplementation of the various deficiencies, and patients 
require regular follow-up throughout their lifespan. This article describes the case of a patient 
with the disease, and reviews literature data on the epidemiology, clinical course, immunoge-
netic aspects, diagnosis and treatment of the syndrome. Arq Bras Endocrinol Metab. 2012;56(1):54-66
SUMÁRIO
Síndrome poliglandular autoimune tipo 1 é uma rara desordem autossômica recessiva carac-
terizada por ataque autoimune a diversos órgãos. A doença é causada por mutações no gene 
AIRE (autoimmune regulator), resultando em uma proteína AIRE defeituosa, proteína esta es-
sencial para a manutenção da autotolerância. As manifestações clínicas são extremamente 
variáveis. A tríade clássica é composta por candidíase mucocutânea crônica, hipoparatiroi-
dismo e insuficiência adrenal, porém diversos outros componentes podem estar presentes. 
A base do tratamento é a reposição das diversas deficiências, e os pacientes devem ser acom-
panhados por toda a vida. Este artigo descreve o caso de uma paciente com a síndrome e 
apresenta uma revisão sobre a epidemiologia, quadro clínico, aspectos imunogenéticos, diag-
nóstico e tratamento da desordem, de acordo com a literatura publicada. Arq Bras Endocrinol Metab. 
2012;56(1):54-66
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case report
INTRODUCTION
Autoimmune polyendocrine syndromes (APS) are rare disorders characterized by the coexistence of 
at least two endocrine gland insufficiencies mediated by 
autoimmune mechanisms (1). Additionally, nonendo-
crine immune diseases may be present. According to the 
Neufeld and Blizzard Classification of 1980 (2), there 
are four main types of APS. Their most relevant features 
are described in table 1. 
 APS type 1, also known as APECED (autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy), 
MEDAC (multiple endocrine deficiency autoimmune 
candidiasis syndrome), juvenile autoimmune polyendo-
crinopathy, or Whitaker’s syndrome (OMIM 240300), 
is classically defined by the association of at least two 
of three major component diseases: chronic mucocuta-
neous candidiasis, primary hypoparathyroidism, and au-
toimmune adrenal insufficiency (2-4). When relatives of 
a patient are analyzed, only one condition is required 
for APS-1 diagnosis (5). Recently, some authors have 
proposed that genetic studies and anti-interferon (IFN) 
antibodies (Abs) should be included as diagnostic cri-
teria (6).
The first description of the association between hy-
poparathyroidism and candidiasis was reported by Thor-
pe and Handley in 1929 (7). However, adrenal insuf-
ficiency was not related to the syndrome until 1946 (8).
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Table 1. Characteristics of the autoimmune polyendocrine syndromes 
(APS)
APS type 1 Chronic candidiasis, hypoparathyroidism,
autoimmune adrenal insufficiency (at least two of them should 
be present)
APS type 2 Autoimmune adrenal insufficiency (must always be present) + 
autoimmune thyroid disease and/or type 1 diabetes mellitus
APS type 3 Autoimmune thyroid disease + other
autoimmune diseases (excluding autoimmune adrenal 
insufficiency, hypoparathyroidism, chronic candidiasis)
APS type 4 Two or more organ-specific autoimmune diseases (which do not 
fall into type 1, 2, or 3)
EPIDEMIOLOGY
The syndrome is rare, and approximately 500 patients 
have been reported worldwide. The highest prevalen-
ce was found among the Iranian Jewish community 
(1:9,000) (9), in Sardinia (1:14,400) (10) and in Fin-
land (1:25,000) (4). There is no published data about 
the prevalence of APS-1 in Brazil.
In most cases, APS-1 appears in infancy or child-
hood (3,4,11,12), and the three major component dis-
eases develop in chronological order: candidiasis first, 
commonly appearing before the age of 5; then hypo-
parathyroidism before the age of 10; and finally, adre-
nal insufficiency, before the age of 15 (4,11-13). One 
report showed that the complete triad was present only 
in 50% of patients at the age of 20, 55% at age 30, and 
40% at age 40 (14), and numbers were similar in other 
reports (4,11). Studies revealed that the earlier the first 
manifestation appears, the greater the number of disea se 
components (3-5,11). The female-to-male ratio varies 
in different reports, from 0.8:1 to 2.4:1 (2-4,11). 
CASE REPORT 
A 28-year-old woman, born to consanguineous parents, 
first presented nail candidiasis and blurred vision at age 5. 
At the age of 17, she developed paresthesia and mus-
cle cramps and, by that time, candidiasis had already 
spread to the skin along her legs and trunk. Three ye-
ars later, diarrhea developed in association with severe 
weakness and worsening tetany. Serum levels of calcium 
were extremely low and PTH was undetectable. The 
patient was then admitted in the medicine service at the 
Universidade Federal de São Paulo, where it was noted 
that, besides hypoparathyroidism and mucocutaneous 
candidiasis, she presented primary amenorrhea with in-
complete pubertal development, nail dystrophy, dental 
enamel hypoplasia, and corneal keratopathy (Figure 1). 
Laboratory tests excluded celiac disease, cystic fibrosis, 
failure of exocrine pancreas, or intestinal infections as 
causes of the chronic diarrhea. Further investigations 
revealed subclinical adrenal insufficiency, pernicious 
anemia, renal tubulopathy, and impaired fasting gluco-
se. Antibodies against pancreatic glutamic acid decar-
boxylase 65 (GAD65), but not against IA-2 and insu-
lin, were positive. Although respiratory symptoms were 
not present, chest computed tomography scan revealed 
bilateral bronchiectasis. The patient is currently under 
treatment with anti-fungal medication and glucocorti-
coid, estrogen, and vitamin B12 replacement. Calcium 
serum levels remain low, even with the administration 
of high doses of calcium supplement and vitamin D de-
rivatives, probably due to malabsorption. The patient 
was submitted to resection of the right cornea and 
transplantation of her own conjuntival cells cultured 
on amniotic membrane, with good results. Now, the 
procedure is scheduled to be performed in her left eye.
CLINICAL MANIFESTATIONS OF APS-1
Chronic mucocutaneous candidiasis (CMC) – Chronic 
superficial infection with Candida albicans is the most 
common manifestation in APS-1. It is present in almost 
100% of the patients, with the exception of Iranian Jews, 
in whom the infection is seldom reported (4,9,12,15). 
In most cases, CMC is the first of the major compo-
nents of APS-1 to appear, often occurring before age 5 
(4,11,12), and its severity is variable. It preferably affects 
the oral mucosa causing a mild form of intermittent an-
gular cheilitis. More severe cases include inflammation 
of most of the oral mucosa, hyperplastic CMC with 
thick white or grey plaques of yeast and hyperkerato-
sis, and atrophic form with thin mucosa and leukoplakic 
areas. The latter are especially troublesome because of 
their carcinogenic potential. Esophageal mucositis with 
substernal pain and dysphagia may occur. Squamous cell 
carcinoma of the mouth or esophagus shows an obscure 
prognosis. Symptomatic intestinal candidiasis includes 
abdominal pain, flatulence and diarrhea. Female patients 
may suffer from vulvovaginitis. Skin and nails may be 
affected but, in the majority of cases, the infection is 
limited to no more than 5% of the skin surface. Genera-
lized candidiasis has only been reported in patients on 
immunosuppressive medication (4,11,12).
Hypoparathyroidism (HP) – HP is usually the first 
endocrine disease to develop during the course of APS-
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1 and it has been reported in 70%-93% of the cases (2-
4,11,12,16). It varies according to gender, affecting 
98% of female patients, but only 71% of male patients 
(17). Interestingly, when adrenal insufficiency is the 
first endocrinopathy, susceptibility to HP appears to be 
reduced (12,17). Many symptoms of hypocalcemia are 
nonspecific, such as paresthesias and muscle cramps. Sei-
zures may occur in more severe cases. Hypomagnesemia 
is common and may complicate the condition (12). 
 Primary adrenal insufficiency (AI) or Addison’s 
disease – The prevalence of AI is 60%-100%, with peak 
incidence around 12 years of age (2-4,11,16). It is a life-
threatening condition that should be rapidly recog nized 
and treated. Symptoms are fatigue, weight loss, salt crav-
ing, hypotension, abdominal pain and increased pigmen-
tation of the skin. It is important to be aware that hypocor-
tisolism and hypoaldosteronism may appear years apart.
Hypergonadotropic hypogonadism – Hypergonado-
tropic hypogonadism appears in 12%-60% of the APS-
1 patients (2-4,11,16), with a prevalence three times 
higher among females (2,4), possibly due to the blood-
testis barrier that protects Leydig cells from an autoim-
mune attack. Half of the affected female patients have 
primary amenorrhea with absence or early interruption 
of spontaneous pubertal development, and others de-
velop premature menopause (12). 
Autoimmune thyroid diseases – Hypothyroidism is 
relatively uncommon, affecting no more than 30% of 
the APS-1 patients. It develops more often following pu-
berty and by middle age, usually before the age of 30 
(4,9,11,12). Hyperthyroidism is extremely rare (12). 
A higher frequency of autoimmune thyroiditis is ob-
served in patients with APS-1 caused by a specific mu-
tation, the G228W missense mutation (18).
Type 1 diabetes mellitus (T1D) – T1D has been 
des cribed in up to 18% of the APS-1 subjects. The high-
est prevalence was seen in Finnish patients (2-4,11,19). 
This syndrome is part of the heterogeneous sprectrum 
of T1D (20,21). 
Pituitary failure and lymphocytic hypophysitis – 
Single or multiple pituitary defects have occasionally 
been described in APS-1. Growth hormone deficiency 
is the most commonly reported defect, but central dia-
betes insipidus and gonadotropin or ACTH deficien-
cies have also been seen. Autoimmune hypophysitis 
rarely affects patients (4,9,11,12,22).
Chronic atrophic gastritis and pernicious anemia 
– Autoimmune gastritis is characterized by gastric mu-
cosa atrophy, selective loss of parietal cells from the gas-
tric mucosa, and submucosal lymphocyte infiltration. 
Vitamin B12 absorption may be impaired, leading to 
pernicious anemia (2,4,9,11,12).
Intestinal dysfunction and malabsorption – The 
prevalence of intestinal dysfunction varies from 15 up 
to 22% (3,4,11). The symptoms consist of chronic or 
periodic constipation, chronic or recurrent diarrhea and 
malabsorption, which cause weight loss, growth retar-
dation and erratic absorption of medications. Although 
it has been considered a nonendocrine manifestation, 
new evidence indicate that an autoimmune attack 
against cells of the gastrointestinal endocrine system 
actually occurs in APS-1 (see the SELF-ANTIBODIES 
section, below). Besides, malabsorption may be at-
tributed to a variety of causes, such as celiac disease, 
cystic fibrosis, failure of exocrine pancreas, intestinal 
infections (Candida, Giardia lamblia and Clostridium 
difficile), and intestinal lymphangectasia (11,12,22). In 
some cases, diarrhea is caused or worsened by the pre-
sence of HP, since hypocalcemia may cause a functional 
deficit in cholecystokinin (23). Then, a vicious cycle 
sets in: hypocalcemia causes malabsorption, which im-
pairs the absorption of calcium and vitamin D, worsen-
ing the hypocalcemic state.
Autoimmune hepatitis – Hepatitis has been de-
scribed in 8%-26% of the cases (3,4,11). Severity is 
varia ble, ranging from an asymptomatic course with 
spontaneous regression, to fulminant necrotizing dis-
ease with extremely high mortality (4,11,12).
Spleen aplasia or hypoplasia – This disorder is pre-
sent in about 10% of children and 20% of adults (12). 
It appears to be due to a progressive autoimmune-me-
diated destruction or vascular insult. Asplenia compro-
mises the immune response to encapsulated bacteria, 
increasing the susceptibility to Pneumococcus infections. 
Suspicion of asplenia can be raised by the presence of 
Howell-Jolly bodies, thrombocytosis, anysocites, poi-
kylocytes, target cells, and burr cells on peripheral 
blood smears (24).
Renal disease – Tubulointerstitial nephritis has been 
described, sometimes with progression to terminal re-
nal failure and need for kidney transplantation (12,25).
Pulmonary disease – Pulmonary disease has been 
sporadically observed in APS-1 patients as primary pul-
monary hypertension (26), or autoimmune bronchiolitis 
and bronchiectasis (27).
Ectodermal dystrophy – The components of ectoder-
mal dystrophy are keratoconjunctivitis, dental enamel 
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hypoplasia and punctate nail defects. The pathomecha-
nism is unknown.
– Keratoconjunctivitis appears in 10%-35% of pa-
tients (3,4,11,12), usually before the age of 5 (4,11,12). 
It is extremely rare among Iranian Jewish patients (9). 
Affected individuals suffer from intense photophobia, 
blepharospasm, lacrimation, and blurred vision. Pro-
gression to blindness may occur. Corneas show irregu-
lar confluent opacities, with bulbar injection of the 
conjunctiva, and subsequent superficial corneal neovas-
cularization (28). 
– Enamel hypoplasia of permanent teeth is observed 
in approximately 80% of the patients (4). This defect 
predisposes them to further damage and cavities.
– Punctate nail dystrophy was also described in 
APS-1 patients (4,11).
Vitiligo – Vitiligo may develop since the first month 
after birth and is present in 8%-25% of the patients. Ex-
tent is highly variable, from spots to almost all corporal 
surfaces (2-4,11,12).
Alopecia – Another component of the syndrome is 
alopecia, which may appear since the first years, with 
increasing prevalence to 40% by middle age. It involves 
the scalp, eyelashes, eyebrows, axilla, and pubis. Alo-
pecia may be present as transient hairless scalp patches, 
but it may become extensive (11,12).
Vasculitis – Recurrent maculopapular, morbilliform 
or urticarial erythema with fever has also been seen in 
APS-1. Skin biopsies performed in some cases revealed 
lymphoplasmacytic vasculitis (4,11).
Other clinical manifestations – Cholelithiasis (24), 
iridocyclitis, optic nerve atrophy, retinal degeneration 
(29), calcified plaques of the tympanic membranes 
(4,14), selective IgA deficiency, hypergammaglobu-
linemia (4), hemolytic anemia (11,12), hypoplastic 
anemia (12), autoimmune thrombocytopenia (25), 
scleroderma (11,14), Sjögren syndrome (11,12,29), 
lichen planus (11,14), hypermineralocorticoidism-like 
state (12,14), reversible metaphyseal dysplasia (30), 
progressive myopathy (31).
THE AIRE GENE AND ITS ENCODED PROTEIN 
APS-1 results from defects in the autoimmune regula-
tor (AIRE) gene (Gen Bank accession Z97990), which 
was identified and cloned simultaneously by two groups 
in 1997 (32,33). The gene, located on chromosome 
21q22.3, is approximately 13 kb in length, and is com-
posed of 14 exons (NCBI RefSeqGene NG_009556.1) 
(Figure 2). 
AIRE encodes a 545-amino acid protein with mo-
lecular weight of approximately 55-58 kDa, which acts 
as a transcriptional regulator binding to DNA as dimer 
and tetramer, but not as a monomer. It strongly binds 
to G-doublets in an A/T-rich environment where the 
preferred motif is a tandem repeat such as ATTG-
GTTA, and/or combined with a TTATTA-box motif 
(34,35). This protein contains several structural motifs 
that are typical of nuclear proteins and transcription 
factors (Figure 3). 
The homogeneously staining region (HSR) at the 
amino-terminal end of the molecule mediates ho-
modimerization (35). A caspase recruitment domain 
(CARD), which is needed for the transactivation activ-
ity of AIRE, overlaps with the homogeneously staining 
region (36). Adjacent to the HSR is a nuclear localiza-
tion signal (NLS) (37) followed by a SAND domain 
(Sp100, AIRE-1, NucP41/75, DEAF-1), with DNA-
binding properties (34). There are four interspersed 
LXXLL motifs, typical of nuclear receptor binding pro-
teins, where protein-protein interactions are thought to 
occur (38). However, in AIRE, the significance of these 
domains is not totally determined. AIRE also contains 
two zinc fingers of the plant homeodomain type (PHD) 
located in the C terminus (32,33). PHD domains are 
restricted to nuclear transcriptional regulators, inclu-
ding coactivators and chromatin modulating proteins 
(39). It has been shown that the first PHD (PHD1) 
of AIRE acts as an E3 ubiquitin ligase, mediating the 
transfer of ubiquitin to specific proteins (40), a pro-
cess involved in innate and adaptive immunity and a va-
riety of other cell processes (Figure 4). However, other 
functional assessments did not support those findings 
(41). A proline-rich region (PRR) that may be involved 
in protein-protein interactions, is located between the 
two PHD domains.
THE ROLE OF AIRE IN AUTOIMMUNITY
The AIRE gene is largely expressed in the thymus, but 
its protein is also found in lymph nodes, spleen, fetal 
liver, and peripheral blood cells (33,37,42,43). Within 
the thymus, AIRE plays an important role in induction 
of T-cell tolerance. The gene is expressed primarily in 
medullary thymic epithelial cells (mTEC), where it pro-
motes ectopic expression of several peripheral tissue-
-restricted self-proteins, resulting in the presentation 
of the self-antigens (Ags), and clonal deletion of the 
T-cells with high affinity for such Ags (42). In addi-
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tion, AIRE is a proapoptotic factor, expressed at the fi-
nal maturation stage of mTECs. Evidence suggests that 
T-cells can also recognize self-Ags indirectly on den-
dritic cells that have enfolded AIRE-induced apoptotic 
mTECs or mTEC fragments (44). The absence of the 
AIRE protein results in a defective negative selection 
of self-reactive T-cells, which escape to the periphery, 
causing a multiorgan attack (Figure 5).
Beyond the control of negative selection of self-reac-
tive T cells, additional mechanisms of AIRE-dependent 
tolerance have been investigated. One of these mech-
anisms is the positive selection of regulatory T-cells 
(Treg), specialized cells that control self-reactive T-cells 
and maintain immune system homeostasis. A study 
showed a lower level of circulating CD4+Foxp3+Treg in 
some APS-1 patients (45). Opposed to this finding, this 
last study cited, and some other studies with Aire-defi-
cient mice did not report differences in absolute num-
bers, relative frequency, and suppressive function of Treg 
(45,46). Thus, the effect of AIRE deficiency on Treg 
production and function still remains to be determined.
AIRE may also control peripheral dendritic cells 
(DC) maturation and function. Indeed, researchers 
have noted abnormalities in peripheral DC function in 
APECED patients (47), although defects were gene-
rally modest, and sometimes contradictory (48). 
Protection against Candida is thought to be T-cell 
mediated, and Th17-associated cytokines, such as IL-
17A, IL-17F, and IL-22, may be implicated in the de-
fense against this fungal infection (49). Recent studies 
in APS-1 patients published that CMC was associated 
with self-antibodies (Abs) against those Th17-associ-
ated cytokines (50,51), and reported defective IL-17F 
and IL-22 responses to Candida albicans Ags (51). It 
seems that there is a normal B-cell response to Candida, 
which prevents the development of systemic candidiasis.
GENETIC ASPECTS
Most frequently, the syndrome displays an autosomal 
recessive inheritance, but a unique autosomal dominant 
mutation of AIRE has been described in an Italian fa-
mily (18). Study in mice and functional analysis of such 
mutation confirmed that the encoded protein has a 
dominant-negative effect (52). 
To date, more than 70 different mutations of the 
AIRE gene have been identified (Human Gene Mutation 
Database – http://www.hgmd.cf.ac.uk), ran ging from a 
single nucleotide change to large deletions, distributed 
throughout the gene. Another helpful site for updating 
the mutations is the AIREbase: mutation registry for au-
toimmune polyendocrinopathy candidiasis-ectodermal 
dystrophy (APECED) (http://bioinf.uta.fi/AIRE-
base/). Table 2 shows coding variations in AIRE gene.
The most common mutations are the nonsense mu-
tation R257X (present in more than 80% of the Finish 
disease alleles) (32,33); the Y85C missense mutation 
(frequently found among the Iranian Jewish community) 
(53); the nonsense mutation R139X (the most common 
in Sardinia) (10); and the deletion 967-979del13 (present 
in Norwegians, British and North-Americans) (54-56). 
In addition, an unpublished personal communication of 
Moraes-Vasconcelos pointed out that the latter is also the 
most common mutation among South-Americans.
Although APS-1 is considered an autosomal reces-
sive disease, few cases show only one defective allele, 
whereas in other reports not a single mutant allele was 
identified in typical APS-1 patients (15,57). As already 
stated above, only one autosomal dominant mutation 
of AIRE has been described up today, the missense mu-
tation G228W (18). Some mutations affecting splicing 
sites have also been reported (56).
Notably, different mutations have not been consis-
tently correlated with specific phenotypes. Individuals 
with exactly the same mutations (even siblings) present 
wide variations in clinical manifestations and course of 
the disease (4,12). Some authors observed exceptions 
and reported few phenotype-genotype associations: 
the R257X mutation is linked to a higher frequency of 
mucocutaneous candidiasis; lower prevalence of candi-
diasis and Addison’s disease are found in the Iranian 
Jewish patients with the missense mutation Y85C; and 
alopecia is more common in individuals with deletion 
967-979del13 (9,50). Autoimmune thyroiditis is usually 
seen in individuals carrying the G228W missense muta-
tion (18). It seems evident that the allelic heterogeneity 
of the AIRE gene provides very little explanation on 
the variation of the phenotype. Therefore, other modi-
fying factors may be involved. Environmental factors 
clearly contribute to the variation in the manifestations, 
but there is evidence that the phenotype is modified by 
other genetic elements.
Since certain alleles in the genes of human leukocyte 
antigen (HLA) class I (A, B, Cw) and class II (DR, DQ, 
DP) are strongly associated with autoimmune diseases, 
such as type 1 diabetes and autoimmune thyroiditis, sev-
eral studies have been performed to define whether they 
have an impact on APS-1. In a study with APS-1 patients 
Autoimmune polyendocrine syndrome type 1
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Figure 5. The role of AIRE in negative selection of autoreactive T cells. A) Normal function; B) APS-1.
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Figure 2. AIRE gene depicted in 14 exons where most frequent mutations 
are placed. (http://www.ensembl.org/Homo_sapiens/Transcript/Summary?
db=core;g=ENSG00000160224).
CARD: caspase recruitment domain; HSR: homogeneously staining region domain; NLS: 
nuclear localization signal; SAND: Sp100, AIRE-1, NucP41/75, DEAF-1; L (LXXLL): nuclear 
receptor-binding motifs; PHD: plant homeodomain type zinc fingers; PRR: Proline-rich region.
Figure 3. Schematic representation of the AIRE protein and its functional 
domains. 
100 200 300 400 500 545 aa
CARD/HSR NLS
L L L L
SAND PHD PRR PHD
a) Dental enamel hypoplasia; b) Corneal opacity; c) Bronchiectasis.
Figure 1. Manifestations of APS1.
Figure 4. 3D NMR-structure of the first PHD finger of AIRE1 protein, 
resolved by Bottomley, et al. 2005 (41).
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Table 2. Synonymous and non-synonymous coding variations in AIRE. Registered SNP (rs) identification and its functional impact on transcriptional factor 
function
Residue Variation ID Type of mutation Changed residues Mutated codon Functional study
1 rs121434258 Non-synonymous coding M, L ATG, TTG Benign
33 rs3746964 Synonymous coding A GCT, GCC -
83 rs121434255 Non-synonymous coding K, E AAG, GAG Probably damaging
101 rs117659629 Non-synonymous coding P, S CCC, TCC Probably damaging
116 rs74162060 Synonymous coding P CCG, CCA -
139 rs121434256 Stop gained R, * CGA, TGA -
143 rs41276642 Non-synonymous coding P, L CCA, CTA Benign
166 rs11910214 Non-synonymous coding P, L CCG, CTG Possibly damaging
179 rs72650674 Synonymous coding, Splice site N AAC, AAT -
183 rs34219046 Non-synonymous coding T, N ACC, AAC Probably damaging
196 rs878081 Synonymous coding S TCC, TCT -
199 rs74162061 Non-synonymous coding V, I GTC, ATC Possibly damaging
227 rs1055311 Synonymous coding G GGC, GGT -
228 rs121434257 Non-synonymous coding G, W GGG, TGG Probably damaging
252 rs34397615 Non-synonymous coding P, L CCG, CTG Benign
257 rs121434254 Stop gained R, * CGA, TGA -
266 rs41277550 Synonymous coding, Splice site P CCC, CCT -
278 rs1800520 Non-synonymous coding S, R AGC, AGG Benign
291 rs56179981 Synonymous coding L CTC, CTT -
301 rs56393821 Non-synonymous coding V, A GTG, GCG Benign
309 rs74162062 Non-synonymous coding I, M ATC, ATG Possibly damaging
328 rs74162063 Non-synonymous coding R, W CGG, TGG Probably damaging
332 rs59281354 Non-synonymous coding, Splice site S, T AGT, ACT Probably damaging
372 rs61737006 Synonymous coding S TCG, TCA -
373 rs79212994 Non-synonymous coding A, V GCG, GTG Benign
399 rs1800521 Synonymous coding A GCT, GCC -
401 rs61737072 Synonymous coding P CCT, CCC -
405 rs72650676 Synonymous coding P CCG, CCA -
416 rs74162064 Synonymous coding P CCC, CCG -
441 rs72650677 Non-synonymous coding T, M ACG, ATG Probably damaging
460 rs55840791 Non-synonymous coding P, S CCA, TCA Benign
468 rs7281600 Synonymous coding T ACG, ACA -
471 rs74203920 Non-synonymous coding R, C CGC, TGC Probably damaging
492 rs72650679 Synonymous coding P CCC, CCT -
526 rs1133779 Synonymous coding D GAT, GAC -
 * Stop codon.
from 12 different countries, Addison’s disease was posi-
tively associated with the HLA-DRB1* 03 allele (relative 
risk RR 8.8). Alopecia was also found to be significantly 
and positively associated with the HLA-DQB1*0302 
(RR 6.6) and DRB1*04 (RR 4.8). The most common 
protective alleles for T1D, DRB1*15 and DQB1*0602, 
appeared similarly protective in APS-1 patients. Several 
other weaker associations were found, but their true sig-
nificance is not known (19). In fact, some HLA poly-
morphisms seem to influence the APECED phenotype, 
although those associations appear to be weaker than in 
common autoimmune diseases. 
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SELF-ANTIBODIES
The autoimmune destructive process is presumed to be 
T-cell mediated, but typically patients display a variety 
of self-Abs against proteins present in the affected or-
gans, frequently intracellular enzymes (Table 3). The 
role of such self-Abs in the destruction remains unclear, 
but they are useful diagnostic markers, and their appe-
arance usually precedes the development of the clinical 
manifestation.
Table 3. Relevant self-antigens in APS-1, and corresponding diseases
APS-1 components Antigens
Adrenal insufficiency 21-OH, 17α-OH, scc
Hypogonadism scc, 17α-OH, TSGA10
Hypoparathyroidism NALP5, CaSR
Hypothyroidism TPO, Tg
Type 1 diabetes GAD65, IA-2, insulin
Gastrointestinal dysfunction TPH, HDC, GAD65
Immune hepatitis CYP1A2, CYP2AC, AADC, TPH, HDC
Immune gastritis H+/K+ ATPase intrinsic factor
Lung disease KCNRG
Vitiligo Melanocyte, SOX9, SOX10, AADC
Alopecia TH, hair follicles
Candidiasis IL -17A, IL-17F, IL-22
21-OH: 21-hydroxylase, 17α-OH: 17α-hydroxylase, scc: side-chain cleavage enzyme, NALP5: 
NACHT leucine-rich-repeat protein 5, CaSR: calcium-sensing receptor, TPO: thyroid peroxidase, 
Tg: thyroglobulin, GAD65: glutamic acid decarboxylase 65, IA-2: protein tyrosine phosphatase, 
TPH: tryptophan hydroxylase, HDC: histidine decarboxylase, CYP1A2 and CYP2AC: cytochromes 
P450 1A2 and 2A6, AADC: aromatic l-amino acid decarboxylase, TH: tyrosine hydroxylase.
Self-Abs against the steroidogenic enzymes 21-hy-
droxylase (21-OH), side-chain cleavage enzyme (scc) 
and 17α-hydroxylase (17α-OH) may be found in APS-
1 patients with Addison’s disease, and at least one of 
these Abs is present in more than 80% of the patients 
(16,58). A study with 90 patients revealed a strong as-
sociation between self-Abs against 21-OH, scc, and 
adrenal insufficiency, with odds ratio of 7.8 and 6.8, 
respectively. The 17α-OH Ab was not shown to be an 
independent marker in this case (16).
Self-Abs against scc and 17α-OH have been impli-
cated in APS-1, as well as gonadal self-Ags, especially 
among female patients (58). Self-Abs against scc, but 
not 17α-OH, were associated with hypogonadism 
(16). Researches revealed that the testis-expressed pro-
tein TSGA10 is also a target of immune reactions in 
male hypogonadal patients (59). 
Parathyroid self-Ags targeted by self-Abs in APS-1 
patients have been identified as the NACHT leucine-
rich-repeat protein 5 (NALP5) (60) and the extracel-
lular domain of the calcium-sensing receptor (CaSR) 
(61). However, other studies have not confirmed CaSR 
as relevant self-Ag (16,60). It seems that the detection 
of CaSR Abs is critically dependent on the type of assay, 
as revealed by a study that analyzed APS-1 patient sera 
for the presence of CaSR Abs using different assays (61). 
Immunoprecipitation detected CaSR Abs in 85.7% of 
the APS-1 patients, while flow cytometry detected CaSR 
Ab reactivity in 50.0%. Immunoreactivity to CaSR was 
not detectable in radiobinding assays in this same study.
Similar to non-APECED patients, thyroid peroxi-
dase and/or thyroglobulin Abs are detectable in pa-
tients with autoimmune thyroiditis (11,62).
Antibodies against pancreatic glutamic acid decar-
boxylase 65 (GAD65), tyrosine phosphatase-like pro-
tein IA-2 and insulin, which are prevalent in T1D, may 
also be detected in individuals with APS-1. However, 
they display different sensitivity, specificity, and predic-
tive value for diabetes. IA-2-Abs are present in a mi-
nority of APS-1 patients with T1D, but they exhibit 
high specificity (96%-100%) (63). On the other hand, 
GAD65-Abs are common in APS-1, but they are not 
independently associated with T1D (16). The Abs di-
rected to GAD in APS-1 react with different epitopes 
compared with the usual Abs found in T1D (64). Based 
on such information, IA-2-Abs seem to be the best pre-
dictor for T1D in APS-1 with little additive informa-
tion provided by GAD65-Abs.
Endocrine cells are present throughout the gastroin-
testinal tract and evidence sustains the idea that gastro-
intestinal dysfunction in APS-1 is actually an endocrine 
manifestation. Identified self-Ags include tryptophan 
hydroxylase (TPH) (16,65), an enzyme involved in 
the synthesis of serotonin, and histidine decarboxylase 
(HDC) (66), the histamine-synthesizing enzyme. The 
presence of these self-Abs was correlated with loss of 
enterochromaffin and enterochromaffin-like cells in 
biopsy specimens. Self-Abs against GAD65 were also 
found to be associated with intestinal failure (16), what 
is actually reasonable, once GAD65 is highly expressed 
in the nervous system, including the neural plexi of 
the gut. The association between gastrointestinal dys-
function and loss of colecystokinin-producing cells was 
demonstrated in a report that described a patient with 
intermittent severe diarrhea and malabsorption (67). 
During the malabsorption period, postprandial serum 
cholecystokinin concentrations were not detectable, and 
cholecystokinin cells could not be identified in duodenal 
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biopsy. However, during episodes of clinical remission, 
cholecystokinin concentrations increased normally in 
response to food, and cholecystokinin cells were identi-
fied. Nevertheless, the authors could not identify Abs 
against enteroendocrine- or cholecystokinin-producing 
cells. Cholecystokinin deficiency as the main cause of 
the patient’s malabsorption is still questionable.
Cytochromes P450 2A6 (CYP2A6), and mainly 
P450 1A2 (CYP1A2), are enzymes that have been 
reported as self-Ags in patients with autoimmune he-
patitis (62,68); aromatic l-amino acid decarboxylase 
(AADC) has also been implicated (68). Other possible 
self-Ags are the enzymes TPH (16) and HDC (66), 
which are also associated with gastrointestinal dysfunc-
tion, as stated above.
The markers of autoimmune gastritis in APS-1 are 
the same found in general population, which are Abs to 
parietal cells (H+K+ATPase) and to intrinsic factor (11).
Researchers have recently identified a putative po-
tassium channel regulator (KCNRG) as a pulmonary 
self-Ag (27). Self-Abs against KCNRG were detected 
in 7 of the 8 patients with respiratory symptoms, but in 
only 1 of 102 APS-1 patients without respiratory mani-
festations. Therefore, these findings bring out the idea 
that pulmonary involvement can be considered another 
autoimmune manifestation of the syndrome.
Self-antibodies to pituitary proteins, such as the tu-
dor domain-containing protein 6 (TDRD6), were also 
identified, but they do not seem to be associated with 
clinical hypopituitarism or hypophysitis in APS-1 pa-
tients (69).
Some patients with APS-1 and vitiligo exhibit com-
plement-fixing melanocyte Abs (11), as well as Abs 
against the transcription factors SOX9 and SOX10 
(70). AADC self-Abs were also found to be associated 
with vitiligo (16), but the relevance of these Abs in the 
syndrome is still uncertain.
Self-Abs to tyrosine hydroxylase (TH) (71), an en-
zyme involved in the synthesis of dopamine, and to 
keratinocytes of the hair follicles (72) were found in 
patients with alopecia.
As previously stated, APS-1 patients may display 
neutralizing self-Abs against IL-17A, IL-17F, and IL-
22 cytokines (50,51). This is thought to be the cause 
of the susceptibility to CMC, since it was noted that 
IL-17F and IL-22 responses to Candida albicans Ags 
were severely reduced. In those two reports, the levels 
of such Abs were low or undetectable in healthy sub-
jects and unaffected relatives.
Besides the tissue-related self-Abs, it has been found 
that APS-1 patients virtually always develop high-titer 
neutralizing type I IFN-alpha and IFN-omega self-Abs 
(6,13). Type I IFNs are known to be antiviral and an-
tiproliferative cytokines, and they also stimulate cyto-
toxic activity in a variety of cells of the immune system. 
Titers of self-Abs to anti-INF are almost always high 
initially and persist for decades, regardless of the exact 
AIRE mutation, gender, ethnic background, and disea-
se components. In contrast, these Abs could not be de-
tected in healthy subjects, unaffected relatives, controls 
with other infectious, autoimmune or neoplastic dis-
eases, with the exception of thymoma and myasthenia 
gravis. Their sensitivity, specificity, and predictive values 
exceed 98%. Therefore, it has been suggested that IFN-
alpha and IFN-omega self-Abs should be included as 
additional diagnostic criteria for APS-1, provided thy-
moma and myasthenia gravis are excluded. 
TREATMENT
The mainstream treatment of this syndrome is to sup-
ply the various deficiencies, which, at first, may seem a 
simple procedure. However, tricky situations are likely 
to arise, which require utmost attention and are detai-
led below.
Patients suffering from HP must receive calcium 
supplement and vitamin D derivatives in a dose suffi-
cient to maintain plasma calcium in the lower half or 
slightly below the normal range, and urinary calcium in 
the normal range. 
As a life-threatening condition, AI should be diag-
nosed before it turns symptomatic. Glucocorticoid 
replacement must be initiated immediately and doses 
have to be increased during periods of acute stress, like 
infections and surgery. It is important to be aware of 
the likelihood of hypocalcemia whenever the glucocor-
ticoid replacement is increased, and to adjust hypopara-
thyroidism treatment accordingly. Mineralocorticoid 
deficiency is managed with fludrocortisone acetate.
L-thyroxin supplementation is administered in case 
of hypothyroidism, always after ruling out or treating 
AI. Thyroid hormone increases hepatic clearance of 
cortisol, and may precipitate adrenal crisis in undiag-
nosed AI. In addition, patients with non-treated AI 
may display a reversible increase in thyrotropin levels, 
since glucocorticoids inhibit thyrotropin secretion.
Estrogen or androgen replacement should start at 
pubertal age in hypogonadal children. Doses should 
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be gradually increased, and treatment should be main-
tained during adulthood.
Vitamin B12 replacement therapy should be given 
whenever necessary.
It is noteworthy that intestinal dysfunction may lead 
to inadequate and erratic absorption of medications. 
Maintaining appropriate levels of hormones and other 
substances may be really challenging in some cases. Mal-
absorption may be improved with oral replacement of 
pancreatic enzymes and by decreasing fat intake or re-
placing common fat by medium-chain triglycerides (14). 
Again, it must be emphasized that hypocalcemia may 
worsen malabsorption and, therefore, must be prevented.
CMC should be controlled with anti-fungal medica-
tion. Azole agents like miconazole, ketoconazole, itra-
conazole, and fluconazole are often effective, although 
long-term use may lead to drug resistance (73,74). 
Another important issue to be remembered is that 
azoles may cause defective steroidogenesis, worsening 
or causing AI. Amphotericin B and nystatin, polyene 
class antifungals, should be preferred. Oral and esopha-
geal candidiasis must be strictly controlled to prevent 
develop ment of squamous cell carcinoma (75). 
Keratitis may be ameliorated with local glucocor-
ticoids, and topical vitamin A may prevent corneal ul-
cerations (22). Corneal transplantation and treatment 
with limbal stem cells have been performed in few cases 
(28,76,77).
Patients with asplenia are recommended to be vacci-
nated against pneumococcus, but some authors suggest 
that every APS-1 patient should be vaccinated, since 
asplenia is commonly asymptomatic (14).
The role of immunosuppressive therapy has been 
reported in several publications, with different drugs. 
Immunosuppressive therapy seems to control malab-
sorption and pancreatic insufficiency, hepatitis, keratitis, 
alopecia, and other symptoms, but with variable results 
(12,22). A young patient with tubulointerstitial nephri-
tis and renal insufficiency received tacrolimus, mycophe-
nolate mofetil, and prednisolone after kidney transplant. 
These medications led to stable renal function and im-
proved hypoparathyroidism, candidiasis, thyroiditis, 
thrombocytopenia, alopecia, and Sjögren syndrome, 
with normalization of self-Ab levels. However, exocrine 
pancreatic insufficiency persisted, and anti-intrinsic fac-
tor Abs remained positive (25). Another patient was 
given cyclosporine-A and presented improvement of 
pancreatic insufficiency, alopecia, and keratitis, but her 
self-Ab levels did not decrease (22). It is important to 
remember that immunosuppressive therapy predispose 
the patient to the spreading of superficial candidiasis to 
a generalized and severe form (4,11,12).
DISCUSSION 
In this paper, we report an emblematic case of APS-1 
that displayed several features described in the litera-
ture. The patient presented the first symptoms during 
childhood, as the majority of the affected individuals. 
The three major components developed in the charac-
teristic chronological order: candidiasis was the first 
to appear when she was 5 years old, and symptoms of 
hypocalcemia appeared at the age of 17, although we 
believe hypoparathyroidism was already present mon-
ths or even years before that. To date, the patient has 
not developed clinical adrenal insufficiency, even though 
tests revealed subclinical disease. Candidiasis affects 
her oral mucosa, skin and nails; as expected, the gene-
ralized disease has not developed, since she has never 
been under immunosuppressive treatment. Like 12%-
60% of the APS-1 patients, this patient suffers from 
hypergonadotropic hypogonadism, and similar to the 
majority of the patients, she has enamel hypoplasia. 
Besides this teeth disorder, ectodermal dysplasia also 
appears in her nails and corneas. Although there are only 
few reports about the treatment of keratopathy with 
stem cell transplantation, the patient has undergone 
the procedure with successful results. Some infrequent 
components of the syndrome, reported only in spora-
dic cases, are also present: tubulointerstitial nephritis 
and bronchiectasis. The patient also displays impaired 
fasting glucose, however the only detectable antibody 
is the one against GAD65. Based on the findings that 
GAD65-Abs do not seem to be a good predictor of 
T1D in APS-1, and that they are found to be associa-
ted with intestinal failure, we believe that, in this case, 
these Abs represent autoimmune gastrointestinal dise-
ase, since her malabsorption had no other clear cause. 
As stated before, treatment may be extremely challen-
ging. In this particular case, the most difficult issue is 
how to maintain appropriate levels of hormones, once 
because of malabsorption medications must be admi-
nistered in uncomfortable high doses.
CONCLUSION
APS-1 is a complex syndrome characterized by multi-
ple-organ damage. Although rare, it must be diagnosed 
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in early stages, given its high morbidity and mortality. 
Treatment and follow-up are demanding and require 
a multidisciplinary approach. The main objective is to 
preserve the patient’s quality of life and psychosocial 
support is essential for most patients. Physicians should 
be able to promptly recognize and treat new disea-
se components, which may develop throughout the 
patient’s lifetime.
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